TG Therapeutics Inc
$ 49.76
0.42%
07 Aug - close price
- Market Cap 7,616,716,000 USD
- Current Price $ 49.76
- High / Low $ 50.19 / 49.11
- Stock P/E 18.16
- Book Value 4.11
- EPS 2.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 1.00 %
- 52 Week High 59.30
- 52 Week Low 25.28
About
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Analyst Target Price
$76.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-06 | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-04 | 2024-08-06 | 2024-05-01 | 2024-02-28 | 2023-11-01 |
| Reported EPS | 0.05 | 0.18 | 0.14 | 0.16 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 | -0.07 | -0.1 | 0.73 |
| Estimated EPS | 0.41 | 0.28 | 0.35 | 0.22 | 0.29 | 0.17 | 0.09 | 0.03 | -0.04 | -0.04 | -0.1 | 0.1 |
| Surprise | -0.36 | -0.1 | -0.21 | -0.06 | -0.12 | -0.14 | 0.06 | -0.01 | 0.08 | -0.03 | 0 | 0.63 |
| Surprise Percentage | -87.8049% | -35.7143% | -60% | -27.2727% | -41.3793% | -82.3529% | 66.6667% | -33.3333% | 200% | -75% | 0% | 630% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TGTX
2026-08-09 06:39:44
Argus has raised its target price for TG Therapeutics, Inc. (TGTX) to $60.00, noting the company's focus on novel treatments for B-cell diseases. The biopharmaceutical company is described as fully integrated and commercial-stage. The current stock price for TGTX is $49.76.
2026-08-08 18:11:37
TG Therapeutics (TGTX) reported a Q2 2026 profit drop despite increased revenue and raised full-year 2026 revenue guidance to approximately US$950 million, driven by confidence in its B-cell disease franchise and anticipated launch of subcutaneous BRIUMVI. While the company projects significant revenue and earnings growth by 2029, investors are advised to consider the risks associated with reliance on a single IV franchise and potential payer pressure on drug pricing.
2026-08-07 21:11:37
TG Therapeutics director Laurence N. Charney gifted a total of 6,050 shares of common stock to a 501(c)(3) institution on August 6-7, 2026. The shares were transferred at $0.00 per share, and Charney retains no beneficial ownership or pecuniary interest in the gifted stock. His remaining holdings include restricted common stock that vests over time.
2026-08-05 21:42:06
This article lists various ETFs that invest in TG Therapeutics, Inc. stocks, providing detailed information such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each fund. The ETFs primarily focus on small-cap, total market, or health care sectors, offering investors diverse options to gain exposure to TG Therapeutics, Inc. through lower-risk investment vehicles.
2026-08-05 21:31:51
TG Therapeutics reported its 2026 quarterly results with revenue of $240.34 million, an increase from $141.15 million in the prior year, and diluted EPS of $0.05, down from $0.17. The net income for the quarter was $7.78 million, compared to $28.19 million in the year-ago period. Revenue growth was primarily driven by increased U.S. penetration and ex-U.S. sales through a partner, along with continued adoption of BRIUMVI following FDA approval and positive clinical trial results for its pipeline.
2026-08-05 21:31:51
TG Therapeutics (NASDAQ: TGTX) reported strong financial results for the first half of 2026, with total revenue reaching $445.3 million, primarily driven by BRIUMVI sales for multiple sclerosis both in the U.S. and internationally. The company achieved profitability, posting a net income of $27.6 million for the period, and anticipates existing liquidity and projected revenues will fund operations for over twelve months without needing to raise additional capital. TG Therapeutics also highlighted progress in its clinical pipeline, including positive Phase 3 topline data for a simplified BRIUMVI dosing regimen and Phase 1 data for subcutaneous ublituximab, alongside initiating new trials for BRIUMVI in myasthenia gravis and schizophrenia.
